Recombinant production of a VL single domain antibody in Escherichia coli and analysis of its interaction with peptostreptococcal protein L

Protein Expression and Purification

Volumn 51, Issue 2, 2007, Pages 253-259

  Cossins, Aimee J ^a   Harrison, Steven ^a   Popplewell, Andrew G ^b   Gore, Michael G ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UCB PHARMA   (Belgium)

Author keywords

Affinity; Domain antibody; Fermentation; Protein L

Indexed keywords

ESCHERICHIA COLI;

ANTIBODY; BACTERIAL PROTEIN; IG L BINDING PROTEIN, PEPTOSTREPTOCOCCUS; IG L-BINDING PROTEIN, PEPTOSTREPTOCOCCUS; IMMUNOGLOBULIN KAPPA CHAIN; PEPTIDE FRAGMENT;

AFFINITY CHROMATOGRAPHY; AMINO ACID SEQUENCE; ANTIBODY COMBINING SITE; ARTICLE; BIOSYNTHESIS; CIRCULAR DICHROISM; ESCHERICHIA COLI; FLUOROMETRY; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; NUCLEAR MAGNETIC RESONANCE; PROTEIN TERTIARY STRUCTURE;

AMINO ACID SEQUENCE; ANTIBODIES; BACTERIAL PROTEINS; BINDING SITES, ANTIBODY; CHROMATOGRAPHY, AFFINITY; CIRCULAR DICHROISM; ESCHERICHIA COLI; FLUOROMETRY; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN VARIABLE REGION; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, TERTIARY;

EID: 33751399676     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2006.07.013     Document Type: Article

References (20)

1. Holt L.J., Herring C., Jespers L.S., Woolven B.P., and Tomlinson I.M. Domain antibodies: protein for therapy. Trends Biotechnol. 21 (2003) 484-490
2. Arbabi-Ghahroudi M., Desmyter A., Wyns L., Haymers R., and Muyldermans S. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett. 414 (1997) 521-526
3. L) intracelluar antibody specific for the amino terminus of huntingtin via yeast surface display. J. Mol. Biol. 342 (2004) 901-912
4. van den Beucken T., van Neer N., Sablon E., Desmet J., Celis L., Hoogenboom H.R., and Hufton S.E. Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains. J. Mol. Biol. 310 (2001) 591-601
5. Chadd H.E., and Chamow S.M. Therapeutic antibody expression technology. Curr. Opin. Biotechnol. 12 (2001) 188-194
6. Humphreys D.P., Carrington B., Bowering L.C., Ganesh R., Sehdev M., Smith B.J., M King L., G Reeks D., Lawson A., and Popplewell A.G. A plasmid system for optimization of Fab′ production in Escherichia coli: importance of heavy and light chain synthesis. Protein Expr. Purif. 26 (2002) 309-320
7. Arbabi-Ghahroudi M., Tanha J., and MacKenzie R. Prokaryotic expression of antibodies. Cancer Metastasis Rev. 24 (2005) 501-519
8. Åkerström B., and Björck L. Protein L: an immunoglobulin light chain-binding bacterial protein. J. Biol. Chem. 264 (1989) 19740-19746
9. Bottomley S.P., Beckinham J.A., Murphy J.P., Atkinson M., Atkinson T., Hinton R.J., and Gore M.G. Cloning, expression and purification of Ppl-1, a kappa-chain binding protein, based upon protein L from Peptostreptococcus magnus. Bioseparation 5 (1995) 359-367
10. Housden N.G., Harrison S., Housden H.R., Thomas K.-A., Beckingham J.A., Roberts S.E., Bottomley S.P., Graille M., Stura E., and Gore M.G. Observation and characterization of the interaction between a single immunoglobulin binding domain of protein L and two equivalents of human κ light chains. J. Biol. Chem. 279 (2004) 9370-9378
11. Weir A.N.C., Nesbitt A., Chapman A.P., Popplewell A.G., Antoniw P., and Lawson A.D.G. Formatting antibody fragments to mediate specific therapeutic functions. Biochem. Soc. Trans 30 (2002) 512-516
12. Graille M., A Stura E., Housden N.G., Beckingham J.A., Bottomley S.P., Beale D., Taussig M.J., Sutton B.J., Gore M.G., and Charbonnier J.-B. Complex between Peptostreptococcus magnus protein L and a human antibody reveals structural convergence in the modes of Fab binding proteins. Structure 9 (2001) 679-687
13. Holliger P., and Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23 (2005) 1126-1136
14. Power B.E., and Hudson P.J. Synthesis of high avidity antibody fragments (scFv multimers) for cancer imaging. J. Immunol. Methods 242 (2000) 193-204
15. Batra S.K., Jain M., Wittel U.A., Chauhan S.C., and Colcher D. Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr. Opin. Biotechnol. 13 (2002) 603-608
16. Sanz L., Blanco B., and Álvarez-Vallina L. Antibodies and gene therapy: teaching old 'magic bullets' new tricks. Trends Immunol. 25 (2004) 85-91
17. Glennie M.J., and Johnson P.W.M. Clinical trials of antibody therapy. Immunol. Today 21 (2000) 403-410
18. Pavlinkova G., Beresford G.W., Booth B.J.M., Batra S.K., and Colcher D. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts. J. Nucl. Med. 40 (1999) 1536-1546
19. Lee M.-H., and Kwak J.-W. Expression and functional reconstitution of a recombinant antibody (Fab′) specific for human apolipoprotein B-100. J. Biotechnol. 101 (2002) 189-198
20. Yang X., Hu W., Li F., Xia H., and Zhang Z. Gene cloning, bacterial expression, in vitro refolding, and characterisation of a single-chain Fv antibody against PreS1(21-47) fragment of HBsAg. Protein Expr. Purif. 41 (2005) 341-348